| Name | Diphenmanil methylsulfate |
| Description | Diphenmanil methylsulfate (Diphemanil mesylate), a quaternary ammonium anticholinergic, binds muscarinic acetylcholine receptors and thus decreases secretory excretion of stomach acids, sweat, and saliva. |
| In vitro | Pharmacokinetic studies indicate that Diphemanil Methylsulphate is slowly absorbed, with a peak time (tmax) of 2-4 hours and an average half-life of 8.35 hours. Within 48 hours, 0.6%-7.4% of the administered dose is recovered in the urine. The compound exhibits poor gastrointestinal absorption, with bioavailability ranging from 15% to 25%. |
| In vivo | Diphemanil Methylsulfate exerts its anticholinergic effects primarily by binding to muscarinic M3 receptors, and it also acts directly on smooth muscle to provide antispasmodic benefits. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (128.37 mM), Sonication is recommended.
H2O : 26 mg/mL (66.75 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Muscarinic acetylcholine receptor | mAChR | Inhibitor | inhibit | Diphenmanil methylsulfate | Diphenmanil | Diphemanil Mesylate | Diphemanil | AChR |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Ethyl (triphenylphosphoranylidene) acetate | Urethane | Hexamethonium Bromide | Ribavirin | Adenine | Mitotane | Choline chloride | Propoxur | N,N-Dicyclohexylcarbodiimide | Arecoline |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Approved Drug Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max |
United States
